IN2014MN01571A - - Google Patents

Info

Publication number
IN2014MN01571A
IN2014MN01571A IN1571MUN2014A IN2014MN01571A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A IN 1571MUN2014 A IN1571MUN2014 A IN 1571MUN2014A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A
Authority
IN
India
Prior art keywords
ocular
steroid
pharmaceutical composition
composition
umol
Prior art date
Application number
Inventor
Keelung Hong
Luke S S Guo
Sheue Fang Shih
Po Chun Chang
Chih Chiang Tsai
hong hui Lin
Yun Long Tseng
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of IN2014MN01571A publication Critical patent/IN2014MN01571A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids with or without cholesterol and a steroid solution comprising an ocular steroid derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5umol per 50ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
IN1571MUN2014 2012-02-10 2013-02-08 IN2014MN01571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597189P 2012-02-10 2012-02-10
PCT/US2013/025390 WO2013119988A1 (en) 2012-02-10 2013-02-08 Pharmaceutical compositions to reduce complications of ocular steroid

Publications (1)

Publication Number Publication Date
IN2014MN01571A true IN2014MN01571A (en) 2015-05-15

Family

ID=48948063

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1571MUN2014 IN2014MN01571A (en) 2012-02-10 2013-02-08

Country Status (18)

Country Link
US (2) US10058616B2 (en)
EP (1) EP2797601B1 (en)
JP (1) JP6231995B2 (en)
KR (1) KR102060210B1 (en)
CN (2) CN104125830B (en)
AU (1) AU2013216861B2 (en)
BR (1) BR112014018393B1 (en)
CA (1) CA2862055C (en)
CY (1) CY1120323T1 (en)
DK (1) DK2797601T3 (en)
ES (1) ES2673330T3 (en)
IN (1) IN2014MN01571A (en)
NZ (1) NZ628124A (en)
PT (1) PT2797601T (en)
RU (1) RU2660585C2 (en)
TR (1) TR201808592T4 (en)
TW (1) TWI620578B (en)
WO (1) WO2013119988A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111415822A (en) * 2020-03-05 2020-07-14 沈阳农业大学 A kind of onion carbon/manganese dioxide array electrode and preparation method and application thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445335A4 (en) * 2016-04-19 2020-03-04 Nanyang Technological University SUBCONJUNCTIVALED DEPOT FORMULATING FORMULATIONS FOR THE EYE MEDICINE DISPENSING
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
BR112020008046A2 (en) 2017-11-21 2020-10-27 Axerovision, Inc. compositions and methods of use for treating abnormal inflammation in periocular secretory glands or on the ocular surface
US12083138B2 (en) * 2018-07-09 2024-09-10 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
WO2020056399A1 (en) 2018-09-16 2020-03-19 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
MX2021007709A (en) 2018-12-27 2021-12-15 Surface Ophthalmics Inc Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease.
RU2716429C1 (en) * 2019-05-29 2020-03-11 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Method of treating recurrent erosion of corneas of various origins
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
SE9100342D0 (en) 1991-02-04 1991-02-04 Astra Ab NOVEL STEROID ESTERS
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
CN100367932C (en) * 2002-11-26 2008-02-13 吉里德科学公司 Method for Drug Loading in Liposomes by Gradients
AU2004210221B2 (en) 2003-02-04 2008-11-20 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
GEP20084520B (en) * 2004-06-23 2008-10-27 Sirion Therapeutics Inc Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
PT1864667E (en) * 2006-06-01 2013-11-18 Novagali Pharma Sa Use of prodrugs for ocular intravitreous administration
EP2037951A2 (en) * 2006-06-22 2009-03-25 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
EP2255788B1 (en) * 2008-02-29 2015-07-22 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
CN101502485A (en) * 2009-03-20 2009-08-12 中国药科大学 Nano cubic liquid crystal dexamethasone preparation for eye and preparation method thereof
CN101926769A (en) 2009-06-24 2010-12-29 天津金耀集团有限公司 Dexamethasone sodium phosphate lipidosome injection
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2011115684A2 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111415822A (en) * 2020-03-05 2020-07-14 沈阳农业大学 A kind of onion carbon/manganese dioxide array electrode and preparation method and application thereof

Also Published As

Publication number Publication date
CA2862055A1 (en) 2013-08-15
CY1120323T1 (en) 2019-07-10
TW201338806A (en) 2013-10-01
TWI620578B (en) 2018-04-11
TR201808592T4 (en) 2018-07-23
CN104125830B (en) 2018-01-16
BR112014018393B1 (en) 2020-09-15
HK1201723A1 (en) 2015-09-11
EP2797601A1 (en) 2014-11-05
ES2673330T3 (en) 2018-06-21
US10058616B2 (en) 2018-08-28
WO2013119988A1 (en) 2013-08-15
KR20150008844A (en) 2015-01-23
CA2862055C (en) 2020-03-10
PT2797601T (en) 2018-06-27
EP2797601B1 (en) 2018-03-21
JP2015506983A (en) 2015-03-05
NZ628124A (en) 2016-06-24
BR112014018393A8 (en) 2017-07-11
RU2660585C2 (en) 2018-07-06
US10350294B2 (en) 2019-07-16
CN107260679B (en) 2020-07-31
AU2013216861A1 (en) 2014-08-07
US20180193461A1 (en) 2018-07-12
RU2014132553A (en) 2016-02-27
CN104125830A (en) 2014-10-29
JP6231995B2 (en) 2017-11-15
BR112014018393A2 (en) 2017-06-20
AU2013216861B2 (en) 2017-05-18
KR102060210B1 (en) 2019-12-27
US20150011520A1 (en) 2015-01-08
CN107260679A (en) 2017-10-20
EP2797601A4 (en) 2015-06-03
DK2797601T3 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
IN2014MN01571A (en)
WO2012021107A3 (en) A liposomal formulation for ocular drug delivery
BR112014008789A2 (en) prevention and treatment of eye conditions
DOP2012000225A (en) PIRROLO-PYRIMIDINE COMPOUNDS AS CDK4 / 6 INHIBITORS
AR091006A1 (en) PROLIPOSOMAL TESTOSTERONE FORMULATIONS
NZ732777A (en) Ionizable cationic lipid for rna delivery
AR084932A1 (en) OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
BR112015022476A2 (en) Liposome Oxaliplatin Compositions for Cancer Therapy
IN2014DN00277A (en)
EA201400392A1 (en) DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPIRIDAZINES AS AGONISTS Rev-Erb
MX2015012201A (en) Modified docetaxel liposome formulations.
WO2008070463A3 (en) Endoxifen methods and compositions
PH12014500510A1 (en) Use of omega fatty acids for treating disease
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112015022415A2 (en) Liposomal cisplatin compositions for cancer therapy
CA2854430C (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
NZ702705A (en) Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
MX376783B (en) Liposome-based immunotherapy
BR112014004732A2 (en) benzothiazolone compound
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
PH12015501407A1 (en) Topical opthalmological pharmaceutical composition containing regorafenib
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2014184726A3 (en) Compounds and their use in therapy
WO2013043744A3 (en) Tricyclic compounds useful as neurogenic and neuroprotective agents